市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | GH Research PLC | 混合的 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.88% |
| 机构持股比例 | 68.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Rtw Investments, Lp | 31 Mar 2026 | 5,933,815 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 1,800,000 |
| Troluce Capital Advisors Llc | 31 Mar 2026 | 990,472 |
| 5Am Venture Management, Llc | 31 Mar 2026 | 572,665 |
| Squadron Capital Management Llc | 31 Mar 2026 | 325,000 |
| Foresite Capital Management Vi Llc | 31 Mar 2026 | 315,492 |
| Boothbay Fund Management, Llc | 31 Mar 2026 | 282,891 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合